drugset
drugset / Trial / NCT02001389

Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308

NCT02001389 ↗

Phase 1 Completed 14 enrolled FORUM Pharmaceuticals Inc
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is an open-label, single-arm, multiple ascending dose Phase I study to assess the dose- and concentration-dependent displacement of \[18F\]MNI-659 \[a PET tracer targeting phosphodiesterase 10 (PDE10)\] by EVP-6308.

Timeline

Start
2013-10
Primary completion
2014-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject EVP-6308 Unknown — —

Indications

No indication recorded.